These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 29903515)

  • 1. The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe.
    Simon TG; Corey KE; Cannon CP; Blazing M; Park JG; O'Donoghue ML; Chung RT; Giugliano RP
    Int J Cardiol; 2018 Nov; 270():245-252. PubMed ID: 29903515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention.
    Bohula EA; Morrow DA; Giugliano RP; Blazing MA; He P; Park JG; Murphy SA; White JA; Kesaniemi YA; Pedersen TR; Brady AJ; Mitchel Y; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2017 Feb; 69(8):911-921. PubMed ID: 28231942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
    Bohula EA; Wiviott SD; Giugliano RP; Blazing MA; Park JG; Murphy SA; White JA; Mach F; Van de Werf F; Dalby AJ; White HD; Tershakovec AM; Cannon CP; Braunwald E
    Circulation; 2017 Dec; 136(25):2440-2450. PubMed ID: 28972004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT.
    Oyama K; Giugliano RP; Blazing MA; Park JG; Tershakovec AM; Sabatine MS; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2021 Oct; 78(15):1499-1507. PubMed ID: 34620406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
    Kato ET; Cannon CP; Blazing MA; Bohula E; Guneri S; White JA; Murphy SA; Park JG; Braunwald E; Giugliano RP
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29151034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
    Cannon CP; Blazing MA; Giugliano RP; McCagg A; White JA; Theroux P; Darius H; Lewis BS; Ophuis TO; Jukema JW; De Ferrari GM; Ruzyllo W; De Lucca P; Im K; Bohula EA; Reist C; Wiviott SD; Tershakovec AM; Musliner TA; Braunwald E; Califf RM;
    N Engl J Med; 2015 Jun; 372(25):2387-97. PubMed ID: 26039521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial.
    Murphy SA; Cannon CP; Blazing MA; Giugliano RP; White JA; Lokhnygina Y; Reist C; Im K; Bohula EA; Isaza D; Lopez-Sendon J; Dellborg M; Kher U; Tershakovec AM; Braunwald E
    J Am Coll Cardiol; 2016 Feb; 67(4):353-361. PubMed ID: 26821621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial.
    Qamar A; Giugliano RP; Bohula EA; Park JG; Jarolim P; Murphy SA; Blazing MA; Califf RM; Cannon CP; Braunwald E; Morrow DA
    J Am Coll Cardiol; 2019 Aug; 74(8):1057-1068. PubMed ID: 31439215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
    Giugliano RP; Cannon CP; Blazing MA; Nicolau JC; Corbalán R; Špinar J; Park JG; White JA; Bohula EA; Braunwald E;
    Circulation; 2018 Apr; 137(15):1571-1582. PubMed ID: 29263150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
    Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White JA; Tershakovec AM; Blazing MA; Braunwald E
    Circulation; 2015 Sep; 132(13):1224-33. PubMed ID: 26330412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease).
    Fras Z; Mikhailidis DP
    Curr Vasc Pharmacol; 2021; 19(5):451-468. PubMed ID: 32720602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial.
    Albers JJ; Slee A; Fleg JL; O'Brien KD; Marcovina SM
    Atherosclerosis; 2016 Aug; 251():454-459. PubMed ID: 27320173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials.
    Thomopoulos C; Skalis G; Michalopoulou H; Tsioufis C; Makris T
    Clin Cardiol; 2015 Dec; 38(12):763-9. PubMed ID: 26282344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (studie IMPROVE-IT)].
    Špinar J; Špinarová L; Vítovec J
    Vnitr Lek; 2014 Dec; 60(12):1095-101. PubMed ID: 25692840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial.
    Bach RG; Cannon CP; Giugliano RP; White JA; Lokhnygina Y; Bohula EA; Califf RM; Braunwald E; Blazing MA
    JAMA Cardiol; 2019 Sep; 4(9):846-854. PubMed ID: 31314050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT).
    Sharma A; Sun JL; Lokhnygina Y; Roe MT; Ahmad T; Desai NR; Blazing MA
    Am J Cardiol; 2019 Apr; 123(8):1193-1201. PubMed ID: 30739657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Nonalcoholic Fatty Liver Disease Fibrosis Score Is Related to Epicardial Fat Thickness and Complexity of Coronary Artery Disease.
    Turan Y
    Angiology; 2020 Jan; 71(1):77-82. PubMed ID: 31018673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
    Lancellotti P; Pierard LA; Scheen AJ
    Rev Med Liege; 2015 Sep; 70(9):450-5. PubMed ID: 26638446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP).
    Mihaylova B; Schlackow I; Herrington W; Lozano-Kühne J; Kent S; Emberson J; Reith C; Haynes R; Cass A; Craig J; Gray A; Collins R; Landray MJ; Baigent C;
    Am J Kidney Dis; 2016 Apr; 67(4):576-84. PubMed ID: 26597925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD).
    Önnerhag K; Hartman H; Nilsson PM; Lindgren S
    Scand J Gastroenterol; 2019 Mar; 54(3):328-334. PubMed ID: 30907181
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 28.